Annual CFI
$249.31 M
+$390.69 M+276.33%
December 31, 2023
Summary
- As of February 12, 2025, DNLI annual cash flow from investing activities is $249.31 million, with the most recent change of +$390.69 million (+276.33%) on December 31, 2023.
- During the last 3 years, DNLI annual CFI has risen by +$872.51 million (+140.00%).
- DNLI annual CFI is now at all-time high.
Performance
DNLI Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
$93.66 M
-$4.91 M-4.99%
September 30, 2024
Summary
- As of February 12, 2025, DNLI quarterly cash flow from investing activities is $93.66 million, with the most recent change of -$4.91 million (-4.99%) on September 30, 2024.
- Over the past year, DNLI quarterly CFI has dropped by -$4.91 million (-4.99%).
- DNLI quarterly CFI is now -44.28% below its all-time high of $168.07 million, reached on June 30, 2023.
Performance
DNLI Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$187.92 M
-$7.25 M-4.02%
September 30, 2024
Summary
- As of February 12, 2025, DNLI TTM cash flow from investing activities is -$187.92 million, with the most recent change of -$7.25 million (-4.02%) on September 30, 2024.
- Over the past year, DNLI TTM CFI has dropped by -$7.25 million (-4.02%).
- DNLI TTM CFI is now -175.38% below its all-time high of $249.31 million, reached on December 31, 2023.
Performance
DNLI TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
DNLI Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +276.3% | -5.0% | -4.0% |
| 3 y3 years | +140.0% | +173.4% | -32.9% |
| 5 y5 years | +186.7% | +173.4% | -32.9% |
DNLI Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +276.3% | -44.3% | +120.7% | -175.4% | at low |
| 5 y | 5-year | at high | +140.0% | -44.3% | +120.7% | -175.4% | +70.4% |
| alltime | all time | at high | +140.0% | -44.3% | +120.7% | -175.4% | +70.4% |
Denali Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $93.66 M(-5.0%) | -$187.92 M(+4.0%) |
| Jun 2024 | - | $98.57 M(-121.8%) | -$180.66 M(+62.5%) |
| Mar 2024 | - | -$453.19 M(-720.4%) | -$111.16 M(-144.6%) |
| Dec 2023 | $249.31 M(-276.3%) | $73.05 M(-27.6%) | $249.31 M(+411.9%) |
| Sep 2023 | - | $100.91 M(-40.0%) | $48.70 M(-232.4%) |
| Jun 2023 | - | $168.07 M(-281.3%) | -$36.79 M(-68.3%) |
| Mar 2023 | - | -$92.72 M(-27.3%) | -$116.22 M(-17.8%) |
| Dec 2022 | -$141.39 M(+553.8%) | -$127.56 M(-927.3%) | -$141.39 M(+159.1%) |
| Sep 2022 | - | $15.42 M(-82.6%) | -$54.58 M(-55.6%) |
| Jun 2022 | - | $88.63 M(-175.2%) | -$123.00 M(+7.8%) |
| Mar 2022 | - | -$117.88 M(+189.3%) | -$114.10 M(+427.6%) |
| Dec 2021 | -$21.63 M(-96.5%) | -$40.75 M(-23.1%) | -$21.63 M(-93.8%) |
| Sep 2021 | - | -$53.01 M(-154.3%) | -$348.22 M(-31.4%) |
| Jun 2021 | - | $97.54 M(-483.9%) | -$507.33 M(-20.1%) |
| Mar 2021 | - | -$25.41 M(-93.1%) | -$635.28 M(+1.9%) |
| Dec 2020 | -$623.21 M | -$367.34 M(+73.2%) | -$623.21 M(+191.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$212.12 M(+597.5%) | -$213.48 M(-543.5%) |
| Jun 2020 | - | -$30.41 M(+128.1%) | $48.13 M(-66.2%) |
| Mar 2020 | - | -$13.33 M(-131.5%) | $142.43 M(-3.6%) |
| Dec 2019 | $147.71 M(-151.4%) | $42.38 M(-14.4%) | $147.71 M(+236.3%) |
| Sep 2019 | - | $49.49 M(-22.5%) | $43.92 M(+12.2%) |
| Jun 2019 | - | $63.88 M(-893.8%) | $39.16 M(+574.6%) |
| Mar 2019 | - | -$8.05 M(-86.9%) | $5.80 M(-102.0%) |
| Dec 2018 | -$287.42 M(+598.2%) | -$61.40 M(-237.3%) | -$287.42 M(-10.5%) |
| Sep 2018 | - | $44.73 M(+46.5%) | -$321.17 M(-8.1%) |
| Jun 2018 | - | $30.53 M(-110.1%) | -$349.37 M(-2.4%) |
| Mar 2018 | - | -$301.27 M(+216.6%) | -$357.82 M(+769.2%) |
| Dec 2017 | -$41.17 M(-81.2%) | -$95.15 M(-675.8%) | -$41.17 M(-176.3%) |
| Sep 2017 | - | $16.53 M(-25.1%) | $53.98 M(+44.1%) |
| Jun 2017 | - | $22.07 M(+43.5%) | $37.46 M(+143.5%) |
| Mar 2017 | - | $15.38 M | $15.38 M |
| Dec 2016 | -$219.00 M(+7052.3%) | - | - |
| Dec 2015 | -$3.06 M | - | - |
FAQ
- What is Denali Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Denali Therapeutics?
- What is Denali Therapeutics annual CFI year-on-year change?
- What is Denali Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Denali Therapeutics?
- What is Denali Therapeutics quarterly CFI year-on-year change?
- What is Denali Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Denali Therapeutics?
- What is Denali Therapeutics TTM CFI year-on-year change?
What is Denali Therapeutics annual cash flow from investing activities?
The current annual CFI of DNLI is $249.31 M
What is the all time high annual CFI for Denali Therapeutics?
Denali Therapeutics all-time high annual cash flow from investing activities is $249.31 M
What is Denali Therapeutics annual CFI year-on-year change?
Over the past year, DNLI annual cash flow from investing activities has changed by +$390.69 M (+276.33%)
What is Denali Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of DNLI is $93.66 M
What is the all time high quarterly CFI for Denali Therapeutics?
Denali Therapeutics all-time high quarterly cash flow from investing activities is $168.07 M
What is Denali Therapeutics quarterly CFI year-on-year change?
Over the past year, DNLI quarterly cash flow from investing activities has changed by -$4.91 M (-4.99%)
What is Denali Therapeutics TTM cash flow from investing activities?
The current TTM CFI of DNLI is -$187.92 M
What is the all time high TTM CFI for Denali Therapeutics?
Denali Therapeutics all-time high TTM cash flow from investing activities is $249.31 M
What is Denali Therapeutics TTM CFI year-on-year change?
Over the past year, DNLI TTM cash flow from investing activities has changed by -$7.25 M (-4.02%)